Cot inhibitor-1COT/Tpl2 inhibitor CAS# 915365-57-0 |
- 3,3'-Diindolylmethane
Catalog No.:BCC1306
CAS No.:1968-05-4
- BAM7
Catalog No.:BCC1397
CAS No.:331244-89-4
- Bendamustine HCl
Catalog No.:BCC1153
CAS No.:3543-75-7
- Betulinic acid
Catalog No.:BCN5524
CAS No.:472-15-1
- Brassinolide
Catalog No.:BCC1438
CAS No.:72962-43-7
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 915365-57-0 | SDF | Download SDF |
| PubChem ID | 11584834 | Appearance | Powder |
| Formula | C27H27Cl2FN8 | M.Wt | 553.47 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : 25 mg/mL (45.17 mM; Need ultrasonic) H2O : < 0.1 mg/mL (insoluble) | ||
| Chemical Name | 6-[[1-[2-(azepan-1-yl)ethyl]triazol-4-yl]methylamino]-8-chloro-4-(3-chloro-4-fluoroanilino)quinoline-3-carbonitrile | ||
| SMILES | C1CCCN(CC1)CCN2C=C(N=N2)CNC3=CC(=C4C(=C3)C(=C(C=N4)C#N)NC5=CC(=C(C=C5)F)Cl)Cl | ||
| Standard InChIKey | ZWFKJFUFYPOTKL-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C27H27Cl2FN8/c28-23-12-19(5-6-25(23)30)34-26-18(14-31)15-33-27-22(26)11-20(13-24(27)29)32-16-21-17-38(36-35-21)10-9-37-7-3-1-2-4-8-37/h5-6,11-13,15,17,32H,1-4,7-10,16H2,(H,33,34) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Cot inhibitor-1 is a COT/Tpl2 inhibitor. References: | |||||
Cot inhibitor-1 Dilution Calculator
Cot inhibitor-1 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.8068 mL | 9.0339 mL | 18.0678 mL | 36.1357 mL | 45.1696 mL |
| 5 mM | 0.3614 mL | 1.8068 mL | 3.6136 mL | 7.2271 mL | 9.0339 mL |
| 10 mM | 0.1807 mL | 0.9034 mL | 1.8068 mL | 3.6136 mL | 4.517 mL |
| 50 mM | 0.0361 mL | 0.1807 mL | 0.3614 mL | 0.7227 mL | 0.9034 mL |
| 100 mM | 0.0181 mL | 0.0903 mL | 0.1807 mL | 0.3614 mL | 0.4517 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Cot inhibitor-1 is a COT/Tpl2 inhibitor.
- Cot inhibitor-2
Catalog No.:BCC1497
CAS No.:915363-56-3
- Bakkenolide IIIa
Catalog No.:BCN7352
CAS No.:915289-60-0
- 3-[4-[(2-Chloro-5-iodophenyl)methyl]phenoxy]tetrahydro-furan
Catalog No.:BCC8601
CAS No.:915095-94-2
- MDV3100 (Enzalutamide)
Catalog No.:BCC1268
CAS No.:915087-33-1
- BEZ235 (NVP-BEZ235)
Catalog No.:BCC3655
CAS No.:915019-65-7
- Palomid 529
Catalog No.:BCC3905
CAS No.:914913-88-5
- INCB024360 analogue
Catalog No.:BCC1647
CAS No.:914471-09-3
- R788 disodium hexahydrate
Catalog No.:BCC5127
CAS No.:914295-16-2
- 9-Aminocamptothecin
Catalog No.:BCN2453
CAS No.:91421-43-1
- 9-Nitrocamptothecin
Catalog No.:BCN8448
CAS No.:91421-42-0
- 25-O-ethylcimigenol-3-O-beta-D-xylopyranoside
Catalog No.:BCN1309
CAS No.:914086-57-0
- PluriSIn #1 (NSC 14613)
Catalog No.:BCC2305
CAS No.:91396-88-2
- ABC294640
Catalog No.:BCC4192
CAS No.:915385-81-8
- WAY 316606
Catalog No.:BCC2052
CAS No.:915759-45-4
- Dovitinib (TKI258) Lactate
Catalog No.:BCC6473
CAS No.:915769-50-5
- Momordicine I
Catalog No.:BCN3058
CAS No.:91590-76-0
- Benidipine HCl
Catalog No.:BCC4395
CAS No.:91599-74-5
- TCS 1102
Catalog No.:BCC4063
CAS No.:916141-36-1
- AC 55541
Catalog No.:BCC3951
CAS No.:916170-19-9
- Gopherenediol
Catalog No.:BCN6582
CAS No.:916236-79-8
- Acetylvirolin
Catalog No.:BCN7041
CAS No.:916264-22-7
- Clinodiside A
Catalog No.:BCN1048
CAS No.:916347-31-4
- Senkyunolide C
Catalog No.:BCC9141
CAS No.:91652-78-7
- Zingiberen newsaponin
Catalog No.:BCN2942
CAS No.:91653-50-8
Identification of Targets of a New Nutritional Mixture for Osteoarthritis Management Composed by Curcuminoids Extract, Hydrolyzed Collagen and Green Tea Extract.[Pubmed:27275599]
PLoS One. 2016 Jun 8;11(6):e0156902.
OBJECTIVE: We have previously demonstrated that a mixture of curcuminoids extract, hydrolyzed collagen and green tea extract (COT) inhibited inflammatory and catabolic mediator's synthesis by osteoarthritic human chondrocytes. The objective of this study was to identify new targets of COT using genomic and proteomic approaches. DESIGN: Cartilage specimens were obtained from 12 patients with knee osteoarthritis. Primary human chondrocytes were cultured in monolayer until confluence and then incubated for 24 or 48 hours in the absence or in the presence of human interleukin(IL)-1beta (10-11M) and with or without COT, each compound at the concentration of 4 mug/ml. Microarray gene expression profiling between control, COT, IL-1beta and COT IL-1beta conditions was performed. Immunoassays were used to confirm the effect of COT at the protein level. RESULTS: More than 4000 genes were differentially expressed between conditions. The key regulated pathways were related to inflammation, cartilage metabolism and angiogenesis. The IL-1beta stimulated chemokine ligand 6, matrix metalloproteinase-13, bone morphogenetic protein-2 and stanniocalcin1 gene expressions and protein productions were down-regulated by COT. COT significantly decreased stanniocalcin1 production in basal condition. Serpin E1 gene expression and protein production were down-regulated by IL-1beta. COT reversed the inhibitory effect of IL-1beta. Serpin E1 gene expression was up-regulated by COT in control condition. CONCLUSION: The COT mixture has beneficial effect on osteoarthritis physiopathology by regulating the synthesis of key catabolic, inflammatory and angiogenesis factors. These findings give a scientific rationale for the use of these natural ingredients in the management of osteoarthritis.
